KCNQ4 Receptor: A Potential Drug Target (G9132)

Target Name: KCNQ4

NCBI ID: G9132

KCNQ4

KCNQ4 Receptor: A Potential Drug Target

Kalbindoceptin (KCNQ4) is a G protein-coupled receptor (GPCR) that is expressed in various tissues and cells throughout the body. It plays a crucial role in the regulation of pain, inflammation, and body temperature. The KCNQ4 receptor is also known as the TrkB receptor, and it is one of the most well-studied GPCRs. This article will focus on the KCNQ4 receptor, its function, and its potential as a drug target.

Functional Importance of the KCNQ4 Receptor

The KCNQ4 receptor is a GPCR that is expressed in the central nervous system (CNS), peripheral nervous system (PNS), and skeletal muscles. It is involved in the regulation of pain, inflammation, and body temperature. The KCNQ4 receptor is also involved in the regulation of the immune system, and it has been shown to play a role in the regulation of pain perception.

The KCNQ4 receptor is composed of an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is responsible for the binding of the receptor to its ligand, while the transmembrane domain is responsible for the transfer of the signal from the receptor to the intracellular domain. The intracellular domain is responsible for the regulation of the receptor's activity.

KCNQ4 Receptor Signaling

The KCNQ4 receptor is involved in the regulation of pain perception and body temperature. When the body is exposed to pain, the KCNQ4 receptor is activated, and this activation sends a signal to the intracellular domain of the receptor. The intracellular domain is responsible for the regulation of the receptor's activity, and it includes several enzymes that are involved in the regulation of pain perception and body temperature.

One of the enzymes that is involved in the regulation of the KCNQ4 receptor is TrkB, which is a key transcription factor that is involved in the regulation of pain perception and body temperature. TrkB is activated by the activation of the KCNQ4 receptor, and this activation sends a signal to the intracellular domain of the receptor. The intracellular domain of the receptor is then responsible for the regulation of the activity of the enzymes that are involved in the regulation of pain perception and body temperature.

Drug Targeting the KCNQ4 Receptor

The KCNQ4 receptor is a potential drug target, and several studies have investigated the effects of drugs that target the KCNQ4 receptor. One of the most well-studied drugs that targets the KCNQ4 receptor is biscuit acid (cbiscuit acid), which is Small molecule compounds that can bind to the KCNQ4 receptor and inhibit its activity.

Biscuit acid inhibits TrkB activity by binding to TrkB receptors, thereby reducing the occurrence of pain and inflammation. In addition, biscuit acid can lower body temperature and enhance immune system function.

In addition, there are other drugs that also target the KCNQ4 receptor, such as triptan (Izatisabtinib), nidazole (Nabumetone) and ACP-157 (Altitocinib). They can all inhibit KCNQ4 receptor activity and are used with For the treatment of pain and inflammation-related conditions.

Conclusion

The KCNQ4 receptor is a GPCR that is involved in the regulation of pain, inflammation, and body temperature. Its activation sends a signal to the intracellular domain of the receptor, where several enzymes are involved in the regulation of its activity. A potential drug target, and several studies have investigated the effects of drugs that target the KCNQ4 receptor. Biscuit acid is a small molecule compound that can bind to the KCNQ4 receptor and inhibit its activity.

Protein Name: Potassium Voltage-gated Channel Subfamily Q Member 4

Functions: Probably important in the regulation of neuronal excitability. May underlie a potassium current involved in regulating the excitability of sensory cells of the cochlea. KCNQ4 channels are blocked by linopirdin, XE991 and bepridil, whereas clofilium is without significant effect. Muscarinic agonist oxotremorine-M strongly suppress KCNQ4 current in CHO cells in which cloned KCNQ4 channels were coexpressed with M1 muscarinic receptors

The "KCNQ4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCNQ4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets